Our pipeline
We are currently running a Phase II trial in acute COVID-19. Clinical supplies have been manufactured and we are seeking partners to help accelerate the development and distribution of our products to ensure broad access as soon as possible.
Pre-clinical
Phase 1
Phase 2
Phase 3
Authorized
Acute COVID-19
3
We are currently investigating the use of ‘005 added to standard of care in hospitalized COVID-19 patients. Endpoints include WHO ranked improvements, 28-day discharge rates, and reduction in inflammatory markers.
Long-COVID
2
We have completed our initial human safety study and are preparing for Phase II studies.
Leishmaniasis
1
We have tested ‘005 in mice and showed positive results. Endpoints included prevention of lesions and improvement in clinical score.
Dengue
1
We are currently running proof-of-concept in-vivo studies in mice with our US-based research collaborators. Initial mouse studies show we are able to increase lifespans in AG129 mice.
Zika
1
We are preparing for in-vivo studies.
HCoV-OC43
1
We have demonstrated efficacy in-vitro.
